American Shared Hospital Services

This non-binding proposal asks shareholders to approve, on an advisory basis, the Company’s compensation of its Named Executive Officers as disclosed pursuant to SEC rules. Management seeks endorsement to signal shareholder support for its pay philosophy and practices, which emphasize performance-based elements (the VCP and Commission Plan), equity-based alignment (restricted stock units), and limited perquisites, and to maintain continuity in its approach to executive incentives. The Board and the independent Compensation Committee recommend a vote FOR, arguing that the program is designed to align executives’ interests with long-term shareholder value while avoiding excessive risk-taking, and pointing to independent consultant input and features such as a clawback policy and mix of cash and equity. Because the vote is advisory, it will not legally bind the Board, but the Board states it will consider the outcome when making future compensation decisions. Important context includes recent pay adjustments for executive transitions in 2025, the fact that executive ownership is substantial (directors and officers ~24% ownership), and that a similar advisory proposal in 2025 received strong support (~97%). Potential investor concerns include the degree of equity dilution (limited by available shares under the Incentive Compensation Plan), the use and targets of variable compensation plans that were not met in 2025 (no VCP payouts due to gate failures), and transitions in CEO roles during 2024–2026 that affected compensation levels. An analyst evaluating this proposal should weigh the structure and rigor of performance metrics and gates, the transparency of disclosure, recent vote outcomes, and alignment of realized pay with actual company performance. While management frames the program as performance-aligned and conservative on dilution, shareholders seeking stronger performance linkage or stricter governance safeguards may still press for enhanced metrics, clearer disclosure of targets, or limits on discretionary awards.

Proposal 3 requests shareholder approval to amend and restate the Company’s Incentive Compensation Plan primarily to extend its expiration by five years. Management frames the request as routine and necessary to preserve the Company’s ability to grant equity and cash incentive awards that it uses to attract, retain and motivate employees and directors, and it explicitly states it is not asking for any increase in the number of shares authorized for issuance. The plan’s mechanics — discretionary grant, stock issuance, incentive bonus and automatic grant programs — remain in place, with per-participant limits, anti-repricing protections, and change-in-control vesting provisions; the Compensation Committee retains broad discretion over award terms. The Board’s recommendation rests on the importance of equity incentives to align management with shareholder interests and on the Company’s stated cautious approach to dilution (approximately 407,000 of 2,580,000 shares remained available as of April 5, 2026). From a governance standpoint, key considerations for investors include the plan’s broad discretion for the administrator, the absence of new shares requested (reducing immediate dilution concerns), the anti-repricing safeguard that requires shareholder approval for certain repricing actions, and the automatic grant program for non-employee directors. Analysts should also note the potential for acceleration provisions on change in control and the plan administrator’s ability to substitute awards, which can affect post-transaction payouts; however, the plan contains limits on per-participant awards and structures intended to preserve tax treatment where relevant. Overall, approval would maintain the company’s existing incentive framework while extending its term; dissenting shareholders would likely focus on the breadth of administrator discretion and whether remaining share availability and award practices adequately protect against undue dilution or excessive executive payouts.

This catch‑all item reserves shareholder consideration of any additional matters properly raised at the meeting. Management includes it as a procedural item to authorize the meeting to consider and act on unforeseen or routine matters not described in the proxy; the Board states it knows of no specific additional proposals. For analysts, the practical significance is limited: this item does not itself set policy or change governance, but it provides flexibility to handle scrivener or late procedural matters and to consider shareholder‑proposed business that satisfied advance notice requirements. If substantive proposals were presented under this heading, they would require disclosure and typically be subject to separate voting requirements; given the Company’s advance notice procedures and Rule 14a‑8 timelines, truly new substantive proposals at the meeting are uncommon. The board’s lack of a recommendation reflects the undefined nature of potential future items; investors should rely on prior disclosure and any supplemental materials the Company provides if material items are added before or during the meeting.